Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-9563 in Mild to Moderate Hypertension (Phase II, China)
CTR20254927Phase 2Active
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Jan 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-9563 in hypertension (HTN), sponsored by Fujian Shengdi Pharmaceuticals. Started Jan 2026; status: active.
02
Drugs
HRS-9563
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on CTR20254927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254927.